Let me give the bull case its due first. The metabolic-drug leaders have genuinely valuable IP: granted method-of-use patents like Eli Lilly's US12616740B2 ("Methods of using a GIP/GLP1 co-agonist for therapy," 2026) protect not just a molecule but how it's deployed. Combine composition, formulation, and method claims and you get a real, layered defense. Nobody should pretend the franchises are unprotected.
Now read the rest of the record. The Street talks about "the" GLP-1 patent as if one wall surrounds the whole field. The filings say otherwise. Sun Pharmaceutical holds its own granted US12622948B2 on "GLP-1/GIP dual agonists" — a competitor with issued claims on the same dual-receptor concept. That is not an empty field with one fortress; it's a neighborhood with several builders.
The contrarian's tell is in the published applications, because they show where the next wave is aiming. US20260151493A1 describes tri-agonists hitting GLP-1, GIP, and the amylin receptor — a deliberate step beyond the incumbents' dual mechanism. When competitors file on the next-generation target, they're not conceding the category; they're trying to leapfrog the patents that cover today's drugs.
Here's the cliff math the deck tends to skip. A composition patent on a specific peptide is strong but finite, and method-of-use claims, while useful, are narrower than they sound — a competitor with a structurally distinct molecule that hits the same receptors may not infringe them. The presence of multiple independent grants on dual agonists is evidence that designing around is feasible, not theoretical.
I'd genuinely like the simple moat story to be true — it makes the franchises easier to value. But the patent landscape is the opposite of simple. It's a crowded, fast-moving estate where incumbents, generic-makers, and challengers are all filing on overlapping mechanisms, and the publications point toward triple-agonist successors that could reset the board.
The grounded takeaway: treat "unbreachable GLP-1 moat" as a claim to verify, not a fact to assume. The grants confirm the leaders have real protection. The same grants — held by competitors — confirm they don't have the field to themselves. Read the assignee on each patent before you price in permanence.